BNZ-1 + Normal saline

Phase 2Withdrawn

0 views this week 0 watching💤 Quiet

Interest: 17/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Alopecia Areata

Conditions

Alopecia Areata, Alopecia Totalis, Alopecia Universalis

Trial Timeline

Oct 1, 2021 → Nov 1, 2022

NCT ID

NCT03532958

About BNZ-1 + Normal saline

BNZ-1 + Normal saline is a phase 2 stage product being developed by Equillium for Alopecia Areata. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT03532958. Target conditions include Alopecia Areata, Alopecia Totalis, Alopecia Universalis.

What happened to similar drugs?

1 of 20 similar drugs in Alopecia Areata were approved

Approved (1) Terminated (0) Active (19)

✅Baricitinib 4 MG Oral TabletEli LillyApproved

🔄CTP-543Sun PharmaceuticalPhase 3

🔄Deuruxolitinib + PlaceboSun PharmaceuticalPhase 3

🔄Baricitinib + PlaceboEli LillyPhase 3

🔄minoxidilJohnson & JohnsonPhase 3

🔄5% Minoxidil + 2% MinoxidilJohnson & JohnsonPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03532958	Phase 2	Withdrawn	Oct 1, 2021	Nov 1, 2022	Alopecia Areata

Competing Products

20 competing products in Alopecia Areata

See all competitors

Product	Company	Stage	Hype Score
Baricitinib	Eli Lilly	Phase 2	42
CTP-543	Sun Pharmaceutical	Phase 2/3	42
CTP-543	Sun Pharmaceutical	Phase 3	40
Deuruxolitinib + Placebo	Sun Pharmaceutical	Phase 3	47
Baricitinib + Placebo	Eli Lilly	Phase 2/3	38
Baricitinib 4 MG Oral Tablet	Eli Lilly	Approved	47
Baricitinib + Placebo	Eli Lilly	Phase 3	47
Baricitinib + Placebo	Eli Lilly	Phase 3	40
minoxidil	Johnson & Johnson	Phase 3	40
5% Minoxidil + 2% Minoxidil	Johnson & Johnson	Phase 3	40
Minoxidil + vehicle of 5% Minoxidil topical foam	Johnson & Johnson	Phase 2	35
5% Minoxidil Topical Foam + Vehicle Topical Foam	Johnson & Johnson	Phase 3	40
Upadacitinib + Upadacitinib Placebo	AbbVie	Phase 3	47
Upadacitinib + Placebo	AbbVie	Phase 3	47
Secukinumab + Placebo	Novartis	Phase 2	27
Daxdilimab	Amgen	Phase 2	35
Ritlecitinib	Pfizer	Pre-clinical	30
LITFULO	Pfizer	Pre-clinical	30
Ritlecitinib	Pfizer	Pre-clinical	33
Ritlecitinib higher dose + Ritlecitinib lower dose + Placebo	Pfizer	Phase 3	47